Abbott Labs Earnings inline, Revenue Beats In Q4

Investing.com – Abbott Labs reported on Wednesday fourth quarter that matched analysts’ forecasts and revenue that topped expectations.

Abbott Labs announced earnings per share of $0.95 on revenue of $8.31B. Analysts polled by Investing.com anticipated EPS of $0.95 on revenue of $8.26B. That was in comparison with EPS of $0.81 on revenue of $7.77B in the same quarter a year before.Abbott Labs had reported EPS of $0.84 on revenue of $8.08B in the previous quarter.Analysts are forecasting EPS of $0.73 and revenue of $8B in the next quarter.

Abbott Labs stock’s are up 3.3% since the start of the year and is trading at $90.26 , still down 0.34% from its 52 week high of $90.04 set on January 21.

Abbott Labs shares gained 0.59% to trade at $90.26 in pre-market trade after the report.

Abbott Labs follows other major Healthcare sector earnings this month

Abbott Labs’s report follows an earnings beat by J&J on Wednesday, who reported EPS of $1.88 on revenue of $20.75B, compared to expected EPS of $1.87 on revenue of $20.78B.

Novocure Ltd had beat expectations on October 31, 2019 with third quarter EPS of $0.02 on revenue of $92.06M, was in comparison with anticipated for EPS of $-0.04 on revenue of $86.94M.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.